Chemistry:25I-NBOH

From HandWiki
Short description: Chemical compound
25I-NBOH
2C-I-NBOH-skeletal.svg
Legal status
Legal status
  • BR: F2
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC17H20INO3
Molar mass413.255 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

25I-NBOH (NBOH-2CI, Cimbi-27, 2-C-I-NBOH) is a derivative of the phenethylamine-derived hallucinogen 2C-I that was discovered in 2006 by a team at Purdue University.

Pharmacology

25I-NBOH acts as a potent agonist of the 5HT2A receptor,[1][2] with a Ki of 0.061 nM at the human 5HT2A receptor, similar to the better-known compound 25I-NBOMe, making it some twelve times the potency of 2C-I itself.

Although in vitro tests show this compound acts as an agonist, animal studies to confirm these findings have not been reported. While the N-benzyl derivatives of 2C-I had significantly increased binding to 5HT2A receptor fragments, compared to 2C-I, the N-benzyl derivatives of DOI were less active compared to DOI.[3]

25I-NBOH is notable as one of the most selective agonist ligands for the 5-HT2A receptor with an EC50 value of 0.074 nM with more than 400 times selectivity over the 5-HT2C receptor.[4]

Analytical chemistry

25I-NBOH is a labile molecule which fragments into 2C-I when analyzed by routine gas chromatography (GC) methods.[5] A specific method for reliable identification of 25I-NBOH using GC/MS has been reported, allowing forensic forces worldwide to correctly identify this compound.[6]

Legality

Sweden

The Riksdag added 25I-NBOH to Narcotic Drugs Punishments Act (sv) under Swedish schedule I ("substances, plant materials and fungi which normally do not have medical use") as of August 18, 2015, published by Medical Products Agency MPA) in regulation HSLF-FS 2015:12 listed as "25I-NBOH" and "2-([2-(4-jodo-2,5-dimetoxifenyl)etylamino]metyl)fenol".[7]

United Kingdom

This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.[8]


Analogues and derivatives

References

  1. "Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers". European Journal of Nuclear Medicine and Molecular Imaging 38 (4): 681–93. April 2011. doi:10.1007/s00259-010-1686-8. PMID 21174090. 
  2. "Theoretical studies on the interaction of partial agonists with the 5-HT2A receptor". Journal of Computer-Aided Molecular Design 25 (1): 51–66. January 2011. doi:10.1007/s10822-010-9400-2. PMID 21088982. Bibcode2011JCAMD..25...51S. 
  3. "Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists". Molecular Pharmacology 70 (6): 1956–64. December 2006. doi:10.1124/mol.106.028720. PMID 17000863. 
  4. "Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists". ACS Chemical Neuroscience 5 (3): 243–9. March 2014. doi:10.1021/cn400216u. PMID 24397362. 
  5. "2A receptor agonist identified in blotter paper seizures in Brazil". Forensic Toxicology 35 (2): 408–414. 2017. doi:10.1007/s11419-017-0357-x. PMID 28706567. 
  6. "Preventing misidentification of 25I-NBOH as 2C-I on routine GC–MS analyses". Forensic Toxicology 35 (2): 415–420. 2017. doi:10.1007/s11419-017-0362-0. http://eprints.lincoln.ac.uk/26957/7/25i-nboh%20aceito.pdf. 
  7. "Gemensamma författningssamlingen avseende hälso- och sjukvård, socialtjänst, läkeme del, folkhälsa m.m.". Lakemedelsverket. https://lakemedelsverket.se/upload/lvfs/HSLF_FS_2015_12.pdf. 
  8. "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014" (in en). http://www.legislation.gov.uk/uksi/2014/1106/made.